← Leaderboards
Valentin V Rybenkov
University Of Oklahoma Norman
$5,087,442
Attributed
$12,253,064
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,253,064 · 9
By mechanism
R01$10,183,443 · 4
R21$2,069,621 · 5
Top collaborators
- Helen I. Zgurskaya8 shared
- John K. Walker6 shared
- Sandrasegaram Gnanakaran5 shared
- Paolo Ruggerone5 shared
- Adam Scott Duerfeldt2 shared
- Derek S Tan2 shared
Most similar at University Of Oklahoma Norman
Same institution · by research overlap
- Helen I. Zgurskaya$18,126,669
Others in their field
Top investigators on “Pseudomonas Aeruginosa”
- Henry F Chambers · Duke University$46,515,637
- Vance G Fowler · Duke University$46,515,637
- Deborah T Hung · Massachusetts General Hospital$24,051,776
- Ryan Cirz · Revagenix, Inc.$22,711,751
- Daniel J Wozniak · Ohio State University$19,184,613
- Alan R Hauser · Northwestern University$18,516,245
Research focus
Pseudomonas AeruginosaPathogenBacteriaCellsAntibioticsResistancePharmaceutical PreparationsAnti-Bacterial AgentsAntibiotic ResistanceInfectionPropertyPharmaceutical ChemistryChromatinLeadGram-Negative BacteriaFamilyDesignPathogenic BacteriaPublic HealthLibrariesSuccessComputer SimulationEscherichia ColiBase
Grant awards (23)
Small-Molecule Penetration and Efflux in Gram-Negative Bacteria$1,203,141
R01 · FY2025 · AI
Atlas of efflux and permeation determinants to advance antibacterial therapeutic discovery$1,120,070
R01 · FY2025 · AI
Chromosome Packing Inhibitors for the Treatment of Eye Infections$226,825
R21 · FY2025 · EY · contact PI
Small-Molecule Penetration and Efflux in Gram-Negative Bacteria$1,241,141
R01 · FY2024 · AI
Chromosome Packing Inhibitors for the Treatment of Eye Infections$201,825
R21 · FY2024 · EY · contact PI
Optimization of efflux avoidance and inhibition for antibiotic development$1,099,291
R01 · FY2022 · AI
Optimization of efflux avoidance and inhibition for antibiotic development$1,106,111
R01 · FY2021 · AI
Optimization of efflux avoidance and inhibition for antibiotic development$1,048,793
R01 · FY2020 · AI
Small molecule inhibitors of bacterial condensins$193,750
R21 · FY2020 · AI · contact PI
Optimization of efflux avoidance and inhibition for antibiotic development$1,056,326
R01 · FY2019 · AI
Small molecule inhibitors of bacterial condensins$232,500
R21 · FY2019 · AI · contact PI
Novel Antimicrobials for Eye Infections$215,173
R21 · FY2019 · EY · contact PI
Optimization of efflux avoidance and inhibition for antibiotic development$1,421,601
R01 · FY2018 · AI
Novel Antimicrobials for Eye Infections$176,423
R21 · FY2018 · EY · contact PI
Structural Chromosome Maintenance in Pseudomonas aeruginosa$225,000
R21 · FY2012 · AI · contact PI
Structural Chromosome Maintenance in Pseudomonas aeruginosa$187,500
R21 · FY2011 · AI · contact PI
Nanomanipulation of analysis of lipoplex assembly$185,625
R21 · FY2010 · EB · contact PI
Nanomanipulation of analysis of lipoplex assembly$225,000
R21 · FY2009 · EB · contact PI
Mechanism of Bacterial SMC Complex MukBEF$181,875
R01 · FY2005 · GM
Mechanism of Bacterial SMC Complex MukBEF$181,875
R01 · FY2004 · GM
Mechanism of Bacterial SMC Complex MukBEF$181,875
R01 · FY2003 · GM
Mechanism of Bacterial SMC Complex MukBEF$181,875
R01 · FY2002 · GM
Mechanism of Bacterial SMC Complex MukBEF$159,469
R01 · FY2001 · GM